I
nfections caused by multidrug-resistant (MDR) Gram-negative bacteria are becoming a major concern among pediatric oncohematological patients undergoing hematopoietic stem cell transplantation (1, 2) . Bacteremia and pneumonia are reported to be the most common infections in this setting (1, 2) , with Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa being the most frequently isolated etiological agents (3, 4) . Of note, among hospitalized children, the rate of infections due to MDR Gram-negative bacteria is reported to range from 9.1% to 39% (4, 5) . Great concern exists not only in relation to the progressive rise of extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae (6, 7) but also in relation to the worrisome emergence of carbapenem-resistant Enterobacteriaceae (8) and extensively drug-resistant P. aeruginosa (2, 9) . Of note, MDR-related infections result in very high mortality rates, ranging between 22.6% and 67% (2, 4, 9) .
Meropenem is a highly potent carbapenem antibiotic, and its use for the treatment of suspected or documented Gram-negativerelated infections is well recognized among febrile neutropenic children (10) (11) (12) (13) .
A standard meropenem dosage of 20 to 40 mg/kg of body weight every 8 h infused over 30 min is deemed effective for attaining a pharmacodynamic target of plasma drug concentration above the MIC (time above the MIC [T ϾMIC ]) for around 40% of the dosing interval in clinically stable children (14) .
However, this dosage schedule might be suboptimal when treating severe Gram-negative infections due to borderline-susceptible pathogens in pediatric hematopoietic stem cell transplant (HSCT) patients.
␤-Lactams have been shown to exhibit faster clearance in pediatric critically ill patients, and higher-than-standard dosages administered by extended or continuous infusion have been recently advocated with the intent of achieving an optimal T ϾMIC in this setting (15) (16) (17) . This approach may be especially relevant when in the presence of pathogens with borderline susceptibility in vitro (18) . Interestingly, extended and/or continuous infusions are being increasingly applied for the administration of ␤-lactams among the pediatric population (19) . This strategy might be especially helpful in treating febrile neutropenic patients (20) , considering that the percentage of T ϾMIC needed for an optimal clinical response rate with meropenem among bacteremic febrile neutropenic adults was almost twice that needed in stable patients (75% versus 40%, respectively) (21) .
The aim of this study was to assess the pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in a population of pediatric HSCT patients who underwent routine therapeutic drug monitoring (TDM) of meropenem for dosage optimization.
MATERIALS AND METHODS
Study design. This retrospective study, carried out in the period between October 2011 and June 2014, included pediatric patients who underwent hematopoietic stem cell transplantation at the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, were treated with con-tinuous-infusion meropenem because of suspected or documented Gram-negative infection, and underwent TDM of meropenem for dose optimization at the Institute of Clinical Pharmacology of the Azienda Ospedaliero-Universitaria of Udine, Udine, Italy. The study was approved by the ethics review board of the IRCCS Burlo Garofolo, and the need for informed consent was waived because each patient's next-of-kin had already provided written informed consent at hospital admission for scientific use of clinical data. All data were retrospectively analyzed and anonymized prior to inclusion.
Meropenem therapy was started empirically with a loading dose, followed immediately afterwards by a continuous-infusion maintenance dose, the amount of which was chosen at the discretion of the attending physician. Continuous infusion was appropriately granted through reconstitution of the solution every 6 to 8 h at the maximum (22) . Subsequently, the meropenem dosage was tailored by means of clinical pharmacological advice based on TDM of plasma concentrations determined on blood samples collected under steady-state conditions (C SS ). C SS data included in this analysis were obtained from patients treated with unmodified dosages of continuous-infusion meropenem for Ն2 days.
TDM-guided dosage adjustments were mirrored to target meropenem C SS in the range between 8 and 12 mg/liter. The rationale behind this is based on the desire to maintain C SS /MIC ratios 4-to 6-fold above the EUCAST clinical breakpoint for meropenem against Enterobacteriaceae and P. aeruginosa (2 mg/liter) (23) (24) (25) . Previous studies suggested that this approach may be helpful in maximizing clinical efficacy while minimizing the risk for the emergence of resistance (23, 26, 27) .
Meropenem concentrations were analyzed by means of a validated high-performance liquid chromatography (HPLC) method with UV detection (28) , with some modifications, as previously described (25, 29) . Precision and accuracy were assessed by performing replicate analyses of quality control samples against calibration standards. Intra-and interassay coefficients of variation were always Ͻ10%. The lower limit of detection was 0.5 mg/liter.
The following demographic and clinical data were retrieved: age, gender, weight, height, duration of therapy, meropenem daily dose and plasma concentrations, type and site of infection, clinical isolate (whenever identified) with susceptibility to meropenem, underlying diseases, and cotreatment with other antimicrobials. The serum creatinine level was assayed at each TDM instance using the Jaffé methodology.
Pharmacokinetic analyses. Individual estimates of meropenem clearance (CL M ) were calculated by means of the formula CL M ϭ IR/C SS , where CL M is the meropenem total body clearance, IR is the meropenem infusion rate, and C SS is the meropenem steady-state concentration. Each CL M estimate was expressed in milliliters per minute per kilogram.
Creatinine clearance (CL CR , expressed in milliliters per minute per 1.73 meters squared) was estimated by means of the original Schwartz formula (30), according to the measurement of serum creatinine level by means of the Jaffé methodology. The relationship between CL M and estimated CL CR was assessed using nonlinear regression analysis.
Monte Carlo simulation and assessment of pharmacokinetic/pharmacodynamic target attainment. A series of 10,000-subject Monte Carlo simulations were conducted in order to evaluate the probability of target attainment (PTA) for five different meropenem dosages (15, 30, The pharmacodynamic targets were a PTA of Ն90% at C SS /MIC ratios of Ն1 and Ն4, which were defined, respectively, as the minimal desired target and optimal desired target for antimicrobial efficacy in this setting.
Four different categories of CL CR were taken into account (40 to Ͻ80, 80 to Ͻ120, 120 to Ͻ200, and 200 to Ͻ300 ml/min/1.73 m 2 ) and were included for simulations with uniform distributions. The CL CR and the meropenem dose directly determined the C SS at each MIC. All simulations were performed with Systat version 13, Systat Software, Inc., USA.
Evaluation of pharmacokinetic/pharmacodynamic (PK/PD) target attainment was determined for those patients in whom microbiological isolates were identified. For those patients having documented polymicrobial infections, a pathogen-specific PK/PD evaluation was calculated for each isolate. The median (interquartile range [IQR]) meropenem C SS was considered for those patients having multiple assessments of meropenem C SS .
Clinical outcome was defined as cured, improved, unchanged, or failed, according to treatment response. A patient was classified as cured if signs and symptoms of the infection disappeared after meropenem treatment, as improved in cases of partial clinical and/or laboratory evidence of response to meropenem, or as unchanged or failed when no favorable clinical response was observed after meropenem treatment. Statistical analysis. The Kolmogorov-Smirnov test was used to assess whether data were normally or nonnormally distributed. Accordingly, the mean Ϯ standard deviation (SD) or median with IQR were used in the descriptive statistics. Regression analysis was conducted with Systat software version 13. A P value of Ͻ0.05 was required to achieve statistical significance.
RESULTS
Twenty-one patients were included in this retrospective analysis. Patient demographics and clinical and microbiological characteristics are described in Table 1 . Fifteen (71%) of these patients had underlying hematological malignancies.
Among the 27 therapy courses that were included in this analysis, 70.4% comprised the coadministration of meropenem with other antibiotics. Amikacin, teicoplanin, tigecycline, linezolid, vancomycin, and colistin accounted for 53, 42, 11, 11, 5, and 5% of the cotreatments, respectively.
Febrile neutropenia and bloodstream infections accounted for most of the indications of meropenem use (77.8%). In 37.0% (10/27) of the courses, microbiological isolates were identified. The most frequently identified was E. coli, followed by P. aeruginosa and K. pneumoniae. Two patients had 2 clinical isolates during the same course of treatment.
Overall, 44 meropenem C SS measurements were retrieved for this analysis. Figure 2 shows the PTA for different dosing regimens of continuous-infusion meropenem at both the minimal and optimal desired pharmacodynamic targets, stratified by CL CR category. Considering the EUCAST clinical breakpoints for Enterobacteriaceae and P. aeruginosa (MICs, 2 and 8 mg/liter for meropenem susceptibility and resistance, respectively), different dosing regimens were needed to achieve PTA, according to the CL CR category ( Fig. 2 and Table 2 ). When considering the minimal desired target of a C SS /MIC ratio of Ն1 at an MIC of 2 mg/liter, 15 mg/kg/day by continuous infusion was shown to ensure a PTA of Ն90% across all four CL CR categories. At an MIC of 8 mg/liter, doses of 15, 30, 45, and 60 mg/kg/day by continuous infusion were needed for a PTA of Ն90% in the CL CR categories of 40 to Ͻ80, 80 to Ͻ120, 120 to Ͻ200, and 200 to Ͻ300 ml/min/1.73 m 2 , respectively. When considering the optimal desired target of a C SS /MIC ratio of Ն4 at an MIC of 2 mg/liter, doses of 15, 30, 45, and 60 mg/kg/day by continuous infusion were needed for optimal PTA in the CL CR categories of 40 to Ͻ80, 80 to Ͻ120, 120 to Ͻ200, and 200 to Ͻ300 ml/min/1.73 m 2 , respectively. At an MIC of 8 mg/liter, a PTA of Ն90% was achievable with doses of 45 and 90 mg/kg/day by continuous infusion only in the CL CR categories of 40 to Ͻ80 and 80 to Ͻ120 ml/min/1.73 m 2 . However, these dosages were unable to achieve a PTA of Ն90% in the CL CR categories of Ͼ120 ml/min/1.73 m 2 . Evaluation of PK/PD target attainment was feasible in 11 out of 27 meropenem courses, thanks to the identification of bacterial clinical isolates (Table 3) . Eight out of these 11 courses occurred in different patients, whereas 3 courses occurred over a 4-month period in the same patient. A C SS /MIC ratio of Ն4 was guaranteed in all courses involving meropenem-susceptible clinical isolates (9/11 [81.8%]). In 2 bacteremic episodes involving meropenemresistant bacteria (carbapenemase-producing K. pneumoniae and E. coli with porin-mediated resistance to meropenem), C SS /MIC values were around 3 (C SS /MIC, Յ3.13 and 2.96, respectively). Clinical cure was recorded in 81.8% of the courses (9/11), whereas two patients died due to the underlying malignancies.
DISCUSSION
This study assessed the pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric HSCT patients with the intent of identifying optimal dosing regimens for the empirical treatment of severe Gram-negative-related infections in relation to different categories of renal function.
The findings showed that meropenem C SS were often far above the desired range at first TDM, and dosage decreases were applied to about half of the cases. This suggests that clinicians, after appropriately loading, often administered maintenance doses of continuous-infusion meropenem that were too high, probably disregarding patient renal function.
Indeed, several studies investigating meropenem pharmacokinetics among pediatric patients of various ages showed that CL CR is the most predictive determinant of CL M (21, (31) (32) (33) . Noteworthy, children undergoing HSCT may have highly variable CL CR (34) . In an old retrospective study among pediatric bone marrow transplant patients, the measured CL CR ranged between 41.34 and 238.94 ml/min/1.73 m 2 (35) . Consistently, knowing how to adjust meropenem dosage according to different categories of CL CR may be very helpful among pediatric HSCT patients.
Unfortunately, CL CR is rarely measured among children, and estimation by means of various formulas is more often applied to daily clinical practice, even in the setting of HSCT (36) .
Among our patients aged 1 to 16 years, the median and IQR of CL CR estimated by means of the original Schwartz equation (37) were similar to those observed previously by other authors in the same setting (38, 39) . Overall, nonlinear regression documented a good sigmoidal relationship between CL CR estimates and CL M (r 2 ϭ 0.733). This is consistent with previous findings showing that CL CR estimates accounted for 52% of CL M in adults (25) and 67.9% of CL M in newborns (33) .
Accordingly, CL CR estimates were deemed reliable for assessment by means of Monte Carlo simulation, with the PTA being achievable with five dosing regimens of continuous-infusion meropenem in relation to four different categories of CL CR estimates.
Previous studies estimated the PTA of meropenem in the general pediatric population when considering the minimum thresh- old of T ϾMIC of 40%. Dosage regimens of 20 and 40 mg/kg every 8 h over 0.5-h intermittent infusions were predicted to achieve a PTA of Ͼ80% against pathogens with MICs up to 0.25 and 0.5 mg/liter in one study (40) , and of Ͼ90% against pathogens with MICs up to 1 and 2 mg/liter in two other studies (14, 17) .
However, none of these studies specifically included HSCT patients who, as a population group, are usually characterized by extremely variable renal function (34) . Additionally, it should not be overlooked that the minimum threshold of 40% T ϾMIC might be suboptimal for the treatment of severe Gram-negative infections with meropenem among pediatric HSCT patients, considering that among adult HSCT patients, percentages of Ͼ75% T ϾMIC were needed for optimal treatment of bacteremia with meropenem (21) .
Consistently, our simulation was targeted to a PTA of Ն90% at C SS /MIC ratios of Ն1 and Ն4. From the clinical standpoint, our analysis suggests that continuous-infusion meropenem at dosages ranging from 15 mg/kg/day to 60 mg/kg/day, in relation to different categories of CL CR , may ensure optimal exposure against Gram-negative pathogens that are fully susceptible to meropenem.
Of note, PK/PD optimization of meropenem may even allow resistance associated with carbapenem-resistant Gram-negative pathogens to be overcome (12, 18) , which nowadays may cause severe life-threatening infections in pediatric oncohematological patients (12, 17) . It has been suggested that meropenem administered by prolonged infusion might be helpful for the treatment of infections due to carbapenem-resistant Enterobacteriaceae and/or P. aeruginosa with an MIC up to 8 mg/liter, provided that it is combined with other in vitro-active anti-Gram-negative antimicrobials (12) .
Interestingly, our analysis suggests that continuous-infusion meropenem at dosages ranging between 15 mg/kg/day and 60 mg/ kg/day, in relation to different categories of CL CR , may be effective against Gram-negative pathogens with an MIC up to 8 mg/liter by ensuring Ն100% T ϾMIC . However, if one considers the optimal pharmacodynamic target of C SS /MIC of Ն4, dosages up to 90 mg/kg/day by continuous infusion might be effective only for patients with CL CR estimates of Ͻ120 ml/min/1.73 m 2 . Conversely, higher meropenem dosages should be considered for optimal exposure in patients with higher CL CR estimates.
In regard to the PK/PD attainment in the assessable cases, we recognize that unfortunately, few conclusions may be drawn from our study. C SS /MIC ratios of meropenem observed in most of the assessable courses were much higher than the optimal desired target of a C SS /MIC ratio of 4. Several patients were cotreated with other anti-Gram-negative-active antibacterials, as often occurs among HSCT patients (13) . In this regard, it is worth mentioning that in one patient who had bacteremia due to a meropenemresistant strain of E. coli (MIC, 8 mg/liter), continuous-infusion meropenem ensuring a C SS /MIC ratio of around 3 coupled with once-daily amikacin was effective. Interestingly, these findings are in agreement with those observed previously in a pediatric cystic fibrosis patient with a pulmonary infection due to a meropenemresistant strain of Inquilinus limosus (MIC, 8 mg/liter). In that case, cotreatment with high-dose continuous-infusion meropenem ensuring C SS /MIC ratios between 2.6 and 5 coupled with once-daily tobramycin was associated with favorable clinical outcome (41) .
Of note, when applying continuous-infusion meropenem, it
should not be overlooked that treatment must always be started with a loading dose of 20 to 40 mg/kg administered over 30 min to promptly achieve therapeutically effective concentrations. Continuous infusion may then be started immediately afterwards and must be granted through the reconstitution of the solution every 6 to 8 h at the maximum. We recognize that our study has some limitations. The retrospective nature of this investigation and the small sample size are the most relevant limitations. Moreover, some amount of CL M variability remained unexplained, as was found in other previous studies. Finally, we are aware that the meropenem doses administered to our patients at start of therapy were often much greater than needed.
In conclusion, our study suggests that continuous-infusion meropenem at dosages up to 90 mg/kg/day, in relation to different categories of renal function, might be effective for the optimal treatment of severe Gram-negative-related infections in pediatric HSCT patients. This approach might even be helpful when infections are due to carbapenem-resistant pathogens with MICs up to
